Added to YB: 2026-06-09
Pitch date: 2026-06-05
VKTX [neutral]
Viking Therapeutics, Inc.
+1.7%
current return
Author Info
No bio for this author
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$3.3B
Pitch Price
$28.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.38
P/E
-6.84
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Will Viking Get Bought in 2026? Key Catalyst Ahead
VKTX (overview): Obesity takeout candidate; VK2735 dual GLP-1/GIP (sub-q Ph3 fully enrolled). $3.6B mkt cap, $600M cash. Prediction mkts ~33% deal-by-2027; options 4:1 call-skew. Pfizer top buyer; Novo defensive, Lilly less urgent. Pivotal VANQUISH data H2'27—reason to wait. ~38% tail, own optionality not base case.
Read full article (2 min)